Cellect Biotechnology Ltd. (APOP) Forms $9.25 Double Bottom; SIRTEX MEDICAL LTD (SXMDF) Shorts Up By 72.22%

January 21, 2018 - By Adrian Erickson

SIRTEX MEDICAL LTD (OTCMKTS:SXMDF) had an increase of 72.22% in short interest. SXMDF’s SI was 3,100 shares in January as released by FINRA. Its up 72.22% from 1,800 shares previously. With 700 avg volume, 4 days are for SIRTEX MEDICAL LTD (OTCMKTS:SXMDF)’s short sellers to cover SXMDF’s short positions. The stock increased 1.06% or $0.15 during the last trading session, reaching $14.3. About 3,144 shares traded or 21.11% up from the average. Sirtex Medical Limited (OTCMKTS:SXMDF) has 0.00% since January 21, 2017 and is . It has underperformed by 16.70% the S&P500.

Cellect Biotechnology Ltd. (APOP) formed double bottom with $8.79 target or 5.00% below today’s $9.25 share price. Cellect Biotechnology Ltd. (APOP) has $55.52 million valuation. The stock increased 5.71% or $0.5 during the last trading session, reaching $9.25. About 143,674 shares traded or 4.49% up from the average. Cellect Biotechnology Ltd. (NASDAQ:APOP) has 0.00% since January 21, 2017 and is . It has underperformed by 16.70% the S&P500.

Analysts await Cellect Biotechnology Ltd. (NASDAQ:APOP) to report earnings on March, 22. They expect $-0.31 EPS, down 3,000.00% or $0.30 from last year’s $-0.01 per share. After $-0.39 actual EPS reported by Cellect Biotechnology Ltd. for the previous quarter, Wall Street now forecasts -20.51% EPS growth.

Sirtex Medical Limited, a life-sciences company, develops and delivers oncology treatments using novel small particle technology in the Asia Pacific, Europe, the Middle East and Africa, and North and South America. The company has market cap of $895.85 million. The Company’s lead product includes SIR-Spheres Y-90 resin microspheres, a targeted radiation therapy for the treatment of liver tumours. It currently has negative earnings.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: